Arthritis news. Anytime. Anywhere.

Two Trials Show Tofacitinib’s Potential

Tofacitinib, a potential new oral treatment for rheumatoid arthritis (RA), has shown to work as well as adalimumab in two phase III trials, though more adverse events are associated with it.

Read more: Lynda Williams, MedWire News, August 2012

Adalimumab is a tumor necrosis factor inhibitor (anti-TNF) large molecule medication taken by infusion. Tofacitinib is a Janus kinase (JAK) inhibitor. Since it is a small molecule medication, it can be made as a pill.